[go: up one dir, main page]

WO2004050064A1 - Procede permettant de fabriquer une formulation a liberation controlee au moyen d'un pastilleur - Google Patents

Procede permettant de fabriquer une formulation a liberation controlee au moyen d'un pastilleur Download PDF

Info

Publication number
WO2004050064A1
WO2004050064A1 PCT/KR2003/000660 KR0300660W WO2004050064A1 WO 2004050064 A1 WO2004050064 A1 WO 2004050064A1 KR 0300660 W KR0300660 W KR 0300660W WO 2004050064 A1 WO2004050064 A1 WO 2004050064A1
Authority
WO
WIPO (PCT)
Prior art keywords
pellet
drug
combination
filament
dissolution
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2003/000660
Other languages
English (en)
Inventor
Ung Kil Jee
Sung Joo Hwang
Jin Kyu Park
Kyung Lae Park
Young Girl Moon
Si Beum Lee
Yong Jin Kwon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centurion Inc
Original Assignee
Centurion Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centurion Inc filed Critical Centurion Inc
Priority to AU2003219575A priority Critical patent/AU2003219575A1/en
Publication of WO2004050064A1 publication Critical patent/WO2004050064A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient

Definitions

  • the present invention relates, in general, to methods of manufacturing a controlled release formulation using a pelletizer, and more specifically, to a preparation method of a pellet-shaped controlled release formulation containing a drug, characterized in that a pellet having a desired size can be produced using an extruding process and a pelletizing process, whereby an amount of the drug in the formulation is maintained at a predetermined level or more, and as well release properties of the drug can be controlled.
  • the drug may be widely used in various amounts according to purposes.
  • the drug since the drug should be accurately administered in a very small amount to humans, drug loss should be minimized during preparation of the formulation. Meanwhile, the drug may be administered in a large amount in some cases.
  • Formula 1 is (R)(-)-5-[2-[[2-(o-ethoxyphenoxy)ethyl]amino]propyl]-2- methoxyberizenesulfoneamide:
  • the prostate gland is enlarged and the bladder outlet is obstructed, and an amount of coi receptor increases in the enlarged prostate gland, whereby prostate smooth muscle is extraordinarily contracted and bladder muscle becomes hypertrophic upon discharging urine.
  • Internal bladder pressure is increased attributable to intense bladder constriction, and mucosa between hypertrophic muscle fibers is subjected to pressure.
  • patients upon evacuation, patients suffer from obstruction of a urinary stream, urgency of voiding, and frequent urination [UROLOGY 51 (Suppl 4A): 1-7, 1998].
  • Tamsulosin or salts thereof are known to be an antagonist of ⁇ adrenoceptors.
  • tamsulosin hydrochloride tamsulosin HC1
  • tamsulosin HC1 functions as an on receptor blocker in the urethra and the prostate region, and also decreases pressure of prostate regions in urethra inner pressure curves, to improve benign prostatic hyperplasia due to prostatomegaly [UROLOGY 58 (Suppl 6A): 42-48, 2001].
  • Korean Patent Laid-open Publication No. 02-0016944 discloses a therapeutic agent of lower urinary tract diseases comprising tamsulosin or pharmaceutically acceptable salts thereof as an effective ingredient.
  • Lower urinary tract disease is regarded as a kind of benign prostatic hyperplasia symptom caused by functional obstruction of lower urinary tracts of males as well as females. As such, it is noted, that disorders of nerves controlling lower urinary tract and organic obstruction of the urethra are not included in the above urinary tract disease category.
  • Females are often afflicted with lower urinary tract diseases.
  • Lower urinary tract disease is caused by dysuria, sclerosis or obstruction of neck of the urinary bladder, urethra syndrome, detrusor-sphincter coordinated insufficiency, unstable bladder, chronic prostatitis, chronic cystitis, prostatalgia, Hinman's syndrome, Fowler's syndrome, psychogenic benign prostatic hyperplasia, benign prostatic hyperplasia due to drug and aging, etc.
  • tamsulosin hydrochloride for treatment of benign prostatic hyperplasia is orally administered in the amount of 0.2-0.4 mg/day [UROLOGY 58 (Suppl 6A) : 42-48, 2001], and preferable administration form is a controlled release formulation which is continuously released.
  • Commercially available Harnal ® capsule (containing 0.2 mg of tamsulosin HC1) sold by Yamanouchi Pharmaceutical Co., Ltd.
  • FLOMAXTM capsule containing 0.4 mg of tamsulosin HC1) sold by Boeringer Ingelheim are known as a controlled release dosage form administered once per day.
  • Japanese Patent Laid-open Publication No. Sho. 62-9 there is disclosed a method of preparing a controlled release formulation of tamsulosin hydrochloride, in which crystalline cellulose and water-insoluble polymer are used as a unit forming material and a dissolution controlling agent, respectively.
  • the above water-insoluble polymer is used in the form of aqueous dispersion, aqueous emulsion or water-containing organic solvent, and examples thereof include acrylate polymers or copolymers, or cellulose derivatives [e.g., commercially available Eudragit L30D-55 (methacrylic acid copolymer LD), Eudragit E30D (ethylacrylate methylmethacrylate copolymer emulsion), Aquacoat ECD-30 (aqueous ethyl cellulose dispersion)].
  • a granular formulation is prepared from the above materials by use of a centrifugal fluid granulating machine, after which such granules are filled into capsules.
  • the above method is advantageous in terms of preparation of dense spherical granules, but is disadvantageous in light of use of very expensive fluid granulating machines, and high product drug price.
  • a base drug such as tamsulosin hydrochloride in a very small amount (0.2 mg)
  • a base drug solution which is sprayed through a spray nozzle, is not mixed with an excipient by air circulating in the granulating machine and is lost, whereby the amount of the drug contained in the formulation may not reach a desired level.
  • an object of the present invention is to provide a method of manufacturing a controlled release formulation using a pelletizer, which is advantageous in terms of preventing drug loss during production of the formulation, and containing a uniform amount of a drug.
  • Another object of the present invention is to provide a method of manufacturing a controlled release formulation using, a pelletizer, characterized in that a pellet to be prepared can be molded to have desired various sizes or multiple layers by adjusting an inner diameter of holes in an extruder and of semicircular grooves between neighboring protruded portions which are formed along rolling surfaces of molding rollers equipped to the pelletizer, therefore resulting in that control of release rates of the drug can be achieved.
  • FIG. 1 is a view schematically illustrating a structure of an extruder used in the present invention
  • FIG. 2a is a perspective view of a pelletizer used in the present invention.
  • FIG. 2b is a left side view of the pelletizer of FIG. 2a;
  • FIG. 2c is a sectional view taken along A-A line shown in FIG. 2b;
  • FIG. 3 is a graph illustrating an amount of tamsulosin HC1 in a controlled release formulation prepared by the method of the present invention
  • FIG. 4 is a graph illustrating the results of dissolution test for the controlled release formulation of the present invention (drug: tamsulosin HC1) and a commercially available product (D ontrolled release formulation of the present invention as a test formulation, O*: commercially available product as a control formulation); and
  • FIG. 5 is a graph illustrating the results of dissolution test for the controlled release formulation of the present invention (drug: phenylpropanolamine hydrochloride).
  • the present invention concerns a method of manufacturing a controlled release formulation comprising the steps of extruding a drag-containing combination to a filament and molding the filament to a pellet.
  • the term 'combination' means a mixture including the drug and various assistant components to have strength and ductility suitable for extrusion. Although strength and ductility required to extrude the combination to the filament may be experimentally determined, cohesion of the combination amounts to 3.0-45 N when the combination is extruded under a pressure of 1000-4000 N.
  • the assistant components contained in the combination are selected from among a dissolution assisting agent (hydrophilic polymer, surfactant) when release of the drug is incomplete, inert diluent, binder, a dissolution inhibitor (this component may function as the binder when the binder is not contained) when controlled release is required; or mixtures thereof.
  • a dissolution assisting agent hydrophilic polymer, surfactant
  • this component may function as the binder when the binder is not contained
  • the manufacturing method of the controlled release formulation comprises the following steps: (a) dissolving at least an effective amount of a drug, and a hydrophilic polymer or a surfactant for use in assisting dissolution of the drug in a suitable solvent, to prepare a mixture;
  • the drag contained in the controlled release formulation is not specifically limited so long as it may be administered in trace amounts to humans as water-insoluble materials.
  • Antiphlogistics and antipyretic analgesics pentazocine, mefenamic acid, naproxen, indomethacin, phenacetin, acetaminophen, aspirin, sodium salicilate, antipyrine, aminopyrine, diclofenac sodium, ibuprofen, piroxicam, nimesulide, etc.;
  • Stenocardia therapeutic agents amyl nitrate, glyceryl trinitrate, isoso bid dinitrate and mononitrate, pentaei thritol tetranitrate, etc.; Hypertension therapeutic agents: enalapril, captopril, amlodipine, clonidine, diltiazem, felodipine, nifedipine, prazocine hydrochloride, etc.;
  • Adrenergic agonists salbutamol sulfate, terbutalin, ephedrine hydrochloride, naphazoline hydrochloride, phenylpropanolamine hydrochloride, etc.;
  • Hyperhpidemia therapeutic agents lovastatin, clofibrate, gemfibrozil, benzafibrate, simfibrate, etc.;
  • H2-receptor antagonists for treating gastro-enteropathy cimetidine, ranitidine, famotidine, cisapride, domperidone, omeprazole, loperamide, mesalazine, etc.;
  • Antibiotics ampicillin, amoxicillin, gentamicin, erythromicin, rifampicin, chloramphenicol, tetracycline, cefalexin, cefazolin sodium, etc.; and Diabetes therapeutic agents for oral administration: tolbutamide, chlorpropamide, acetohexamide, glibenclamide, metformin hydrochloride, phenformin hydrochloride, etc..
  • the hydrophilic polymer or surfactant used to assist dissolution of the above drag is not specifically limited so long as it may function to dissolve the above drug in a suitable solvent, for example, water, ethanol or a mixture of water and ethanol to control release properties of the drug.
  • hydrophilic polymer is pharmaceutically acceptable, and is available in cases where the amount of the drag is very small or solubility thereof is considerably low.
  • the hydrophilic polymer is exemplified by polyvinylpyrrolidone, polyvmyl alcohol, cellulose derivatives such as hydroxypropylmethylcellulose, or polyethylene oxide.
  • the surfactant is pharmaceutically acceptable and includes any material so long as it may function to assist dissolution of the drag.
  • a surfactant is exemplified by polyethyleneglycol, poloxamers, sodium lauryl sulfate (SLS), etc.
  • the weight ratio of the hydrophilic polymer or surfactant to the drug is 0.5 :1 ⁇ 100:1, depending on release profiles of the drug. When release of the drag is slow or incomplete, the amount of the used hydrophilic polymer or surfactant increases. Alternatively, a bioavailabihty enhancer is used alone or together with the above surfactant.
  • bioavailabihty enhancer means a material assisting dissolution and absorption of the drug in the body to enhance bioavailabihty of the drug.
  • the bioavailabihty enhancer is selected from the group consisting of lauroyl macrogol-32 glyceride, stearoyl macrogol-32 glyceride, propylene glycol monocaprylate, oleoyl macrogol-6 glyceride, linoleoyl macrogol-6 glyceride, caprylocaproyl macrogol-8 glyceride, propylene glycol monolaurate, polyglyceryl-6 dioleate, or mixtures thereof.
  • a fatty acid component is used in the state of being warmed and melt- mixed, or a binder is used alone or used together with the above surfactant.
  • the fatty acid is pharmaceutically acceptable, and is not specifically limited so long as it may function to extend release of the drug.
  • a fatty acid includes glyceryl behenate, glyceryl monooleate, glyceryl monostearate, glyceryl palmitostearate, or mixtures thereof.
  • the fatty acid is preferably added 0.5-50 times to the weight of the drag when being dissolved together with the drug.
  • the binder comprises water-soluble polymers, which are exemplified by cellulose derivatives mcluding methyl cellulose, ethyl cellulose, hydroxypropyl cellulose or hydroxypropylmethylcellulose, alginic acid, sodium alginate, acacia, guar gum, polymethacrylate, or mixtures thereof.
  • the binder may simultaneously function as a dissolution inhibitor. In such a case, it is used in 10-45 wt%. Otherwise, the binder may be used in 5-10 wt%.
  • the controlled release formulation of the present invention comprises a pharmaceutically acceptable diluent, which is exemplified by microcrystalline cellulose, cellulose powders, cellulose acetate, calcium phosphate, calcium sulfate, corn starch, lactose, mannitol, polyvinylpyrrolidone, talc, dexrrate and dextrin, glucose, fructose, maltose, sucrose, kaolin, magnesium carbonate, magnesium oxide, polymethacrylate, or mixtures thereof.
  • the diluent is preferably used in about 25wt% or more on the basis of the whole weight of the controlled release formulation.
  • the order of the above steps (a) and (b) may be variably performed. That is, the step (a) is firstly performed and then the step (b) may be performed or vice versa. Any case is included in the scope of the present invention, and in particular, operation of the step (a) following the step (b) is described in Example 2, later.
  • the controlled release formulation should be obtained in the pellet form using a pelletizer.
  • the mixture of the drug and the dissolution assisting agent should have suitable strength and ductility.
  • the dissolution inhibitor functioning as the binder at the same time, is suitably added to the mixture.
  • the dissolution inhibitor includes the above mentioned fatty acids, cellulose derivatives, gelatin, guar gum, xanthan gum, acrylate homopolymers or copolymers, or mixtures thereof.
  • dissolution inhibitor More particular examples of the dissolution inhibitor are as follows.
  • Compritol 888 ATO glyceryl behenate
  • Precirol ATO 5 glycerylpalmitostearate
  • the cullulose derivative includes AnyCoat (cellulose derivative), or Surelease (25 wt% aqueous ethyl cellulose dispersion added with plasticizer).
  • the acrylate copolymers include Eudragit L30D-55 (copolymer of methacrylic acid and ethyl acrylate), Eudragit RL30D (copolymer of ethyl acrylate and methylmethacrylate introduced with trimethylammomoethyl methacrylate chloride), Eudragit RS30D (copolymer of ethyl acrylate and methyl methacrylate introduced with trimethylammomoethyl methacrylate chloride), Eudragit NE30D (copolymer of ethylacrylate and methyl methacrylate), etc.
  • the dissolution inhibitor may be used in the form of powders, aqueous dispersion, aqueous emulsion, or water-containing organic solvent.
  • the dissolution inhibitor in the form of powders is used in the amount of 10-45 wt%, and includes at least one component.
  • the inhibitor is used in the amount of 50-150 wt%.
  • the dissolution inhibitor when in the form of aqueous dispersion, it may further include 2-5 wt% of a plasticizer selected from among polyethylene glycol, propylene glycol, glycerol, dimethylphthalate, dibutylphthalate, dibutylsebacate, triethylcitrate, tributylcitrate, triethylacetylcitrate, triacetin, castor oil, etc.
  • a plasticizer selected from among polyethylene glycol, propylene glycol, glycerol, dimethylphthalate, dibutylphthalate, dibutylsebacate, triethylcitrate, tributylcitrate, triethylacetylcitrate, triacetin, castor oil, etc.
  • a filler or a colorant may be contained in the controlled release formulation of the present invention.
  • the combination obtained from the above step (b) should have strength and ductility required to perform a filament molding process by extrusion and a pellet molding process. Although strength and ductility required to extrude the combination to the filament may be experimentally determined, cohesion of the combination reaches 3.0 to 45
  • FIG. 1 there is shown a schematic structure of an extruder used in the present invention.
  • An extruding process is performed by use of a hydraulic extruder 1 having a réelle.
  • the combination having suitable strength and ductility is introduced into the extruder 1 and molded to a cylindrical filament.
  • FIGs. 2a and 2b are a perspective view and a left side view of a pelletizer used to mold the extruded filament to the pellet, respectively. Further, FIG. 2c is a sectional view of A- A line shown in FIG.2b.
  • the pelletizer is equipped with a pair of molding rollers 4 and 5 useful to mold the filament to the pellet.
  • the molding rollers 4 and 5 are composed of semicircular grooves 6 and protruded portions 7 along each rolling surface, in which the grooves 6 having a predetermined inner diameter are formed perpendicular to a rotation shaft and also are disposed between neighboring protruded portions 7 functioning to cut an extradate.
  • the molding rollers 4 and 5 are rotated in opposite directions while the top roller 4 comes into mutual contact with the bottom roller 5. As such, the protruded portions 7 of the top and bottom rollers 4 and 5 are brought into mutual contact.
  • a long cylindrical filament 3 is placed parallel to the rotation shaft between the contact surfaces of the two rollers 4 and 5.
  • the extradate is cut by the protruded portions 7 of the rollers 4 and 5 and compressed by the semicircular grooves 6 while being rotated by the two rollers respectively rotating at different speeds, thereby preparing the pellet having a predetermined diameter.
  • the size of the final pellet obtained from the step (c) as mentioned above is controlled by adjusting an inner diameter of the plurality of holes 2 in the extrader 1 or a size of the grooves 6 between adjacent protruded portions 7 of the molding rollers 4 and 5 provided to the pelletizer.
  • the step (b) of forming the combination as mentioned above comprises the steps of:
  • the inert diluent and the dissolution inhibitor used at the steps (bl) and (b2) are as defined above.
  • the granulating operation of the step (bl) accords to general methods using a cylindrical granulating machine, or oscillator granulating machine.
  • the present invention further comprises the step (d) of coating the pellet with a coating agent for controlled release, after the step (c) of preparing the pellet.
  • the coating agent for controlled release includes enteric coating materials or non- enteric coating materials.
  • the enteric coating material is exemplified by cellulose acetate phthalate (CAP), Eudragit L and S types of acrylate copolymers, hydroxypropyl methylcellulose phthalate (HPMCP), polyvinyl acetate phthalate (PNAP), etc.
  • examples of the non-enteric coating material include hydroxypropyl methylcellulose (HPMC), methylhydroxy ethylcellulose (MHEC), ethylcellulose (EC), hydroxypropylcellulose (HPC), povidone (PNP), sodium carboxymethylcellulose (Sod. CMC), propylene glycols (PEGs), acrylate copolymers (Eudragit E, RL and RS types).
  • the coating agent for controlled release is not specifically limited so long as it may be dissolved in or diluted with an organic solvent, such as alcohol, acetone, methylene chloride, or a mixture of water and the organic solvent.
  • This component is used in the amount of 1.5-30wt% according to various viscosities.
  • the coating agent is added with 2-5 wt% of a plasticizer, which is exemplified by polyethyleneglycol, propyleneglycol, glycerol, dimethylphthalate, dibutylphthalate, dibutylsebacate, triethylcitrate, tributylcitrate, triethylacetylcitrate, triacetin, castor oil, etc.
  • the above commercially available material may be used in the state of being diluted with a suitable solvent.
  • a coating process using the above coating agent may be performed by means of a known system. In this regard, there is a spray pan coating system under operation conditions of pan temperatures of 35-40°C, rotation speeds of 55-60 rpm, and spray speeds of the coating agent of to be sprayed through a nozzle of 2-5 ml/min. In addition, a fluid bed coating process may be used.
  • the method of the prevent invention further comprises, after the step (c) of preparing the pellet, the steps of:
  • step (f) extruding the combination to a filament, which is then molded to a final pellet.
  • the diluent and the dissolution inhibitor of the step (e) are defined as in the above step (b).
  • an extrader and a pelletizer used in the above steps (e) and (f) comprise holes and grooves having inner diameters 1.5-2.5 times larger than the holes of the extruder and the grooves between neighboring protruded portions of the molding rollers equipped to the pelletizer used in the above step (c) of preparing the primary pellet.
  • pellets having at least double layers may be prepared.
  • tamsulosin hydrochloride was dissolved in a proper amount of ethanol, together with polyvinylpyrrolidone (PNP K-30) or poloxamer (Lutrol F 127).
  • PNP K-30 polyvinylpyrrolidone
  • poloxamer Litrol F 127
  • the solution was combined with microcrystalhne cellulose (Avicel PHI 02) and granulated by use of a cylindrical granulating machine having a 20 mesh (850 ⁇ m) sieve, to form primary granules, which were then dried at 50 °C for 6 hours.
  • the primary granules were further combined with microcrystalline cellulose
  • tamsulosin hydrochloride and poloxamer (Lutrol F 127) were dissolved in ethanol.
  • the solution was combined with microcrystalline cellulose (Avicel PHI 02) and granulated by use of a cylindrical granulating machine having a 20 mesh (850 ⁇ m) sieve, to form primary granules, which were then dried at 50 °C for 6 hours.
  • the primary granules were further combined with microcrystalline cellulose (Avicel PH102), and Eudragit L30D-55, NE30D, RS30D and RL30D each comprising 30wt% aqueous dispersion as an acrylate copolymer, added with 5 wt% of triethylcitrate.
  • microcrystalline cellulose Avicel PH102
  • Eudragit L30D-55, NE30D, RS30D and RL30D each comprising 30wt% aqueous dispersion as an acrylate copolymer, added with 5 wt% of triethylcitrate.
  • a solution of tamsulosin hydrochloride and poloxamer (Lutrol F 127) in ethanol was mixed with warmed glyceryl behenate (Compritol 888 ATO) for use in retarding dissolution.
  • This solution was combined with a mixture powder of microcrystalline cellulose (Avicel PHI 02), glyceryl behenate (Compritol 888 ATO) and hydroxypropyl methylcellulose (60SH 50, 60SH 4,000), along with water.
  • the combination was granulated by use of a cylindrical granulating machine having a 20 mesh (850 ⁇ m) sieve, to form primary granules, which were then dried at 50 °C for 6 hours.
  • the primary granules were uniformly mixed with microcrystalline cellulose (Avicel PH102) and hydroxypropyl methylcellulose (60SH 50, 90SH 4,000, 90SH 100,000), and further combined with Eudragit RS30D comprising 30wt% aqueous dispersion, or Surelease comprising 25wt% aqueous ethyl cellulose dispersion added with a plasticizer, or water-diluted Surelease.
  • microcrystalline cellulose Avicel PH102
  • hydroxypropyl methylcellulose 60SH 50, 90SH 4,000, 90SH 100,000
  • Eudragit RS30D comprising 30wt% aqueous dispersion
  • Surelease comprising 25wt% aqueous ethyl cellulose dispersion added with a plasticizer, or water-diluted Surelease.
  • the prepared pellet had a particle size of 1.0-5.0 mm, and a large percentage of the pellet were 1.5-2.5 mm in size.
  • an ethanol solution of tamsulosin hydrochloride and poloxamer (Lutrol F 127) or an ethanol/water solution of tamsulosin hydrochloride, poloxamer (Lutrol F 127) and hydroxypropyl methylcellulose (90SH 4,000) was uniformly mixed with microcrystalline cellulose (Avicel PHI 02) and hydroxypropyl methylcellulose (90SH 4,000, 90SH 100,000), and then combined with a proper amount of water or Eudragit RS30D.
  • the combination was granulated by use of a cylindrical granulating machine having a 20 mesh (850 ⁇ m) sieve, to form primary granules, which were then dried at 50°C for 6 hours.
  • the primary granules were uniformly mixed with microcrystalline cellulose (Avicel PHI 02) and hydroxypropyl methylcellulose (60SH 50, 90SH 4,000, 90SH 100,000), and further combined with Surelease comprising 25wt% aqueous etliyl cellulose dispersion added with a plasticizer, or Eudragit L30D-55.
  • the prepared pellet had a particle size of 1.0-5.0 mm, and a large percentage of the pellet were 1.5-2.5 mm in size.
  • tamsulosin hydrochloride and 0.05g of poloxamer were dissolved in ethanol.
  • the ethanol solution was uniformly mixed with 4.0g of microcrystalline cellulose (Avicel PHI 02), and 4.0g of magnesium stearate.
  • the combination was granulated by use of a cylindrical granulating machine having a 20 mesh (850 ⁇ m) sieve, to form primary granules, which were then dried at 50 °C for 6 hours.
  • the primary granules were uniformly mixed with 4.0g of microcrystalline cellulose (Avicel PHI 02) and 4.0g of magnesium stearate, and further combined with 3.6g of Eudragit RS30D and Eudragit L30D-55 each comprising 30wt% aqueous dispersion, added with about 3wt% of triacetin as a plasticizer.
  • the prepared pellet had a particle size of 1.0-5.0 mm, and a large percentage of the pellet were 1.5-2.5 mm in size.
  • tamsulosin hydrochloride and 0.05g of poloxamer were 15 dissolved in ethanol.
  • the ethanol solution was uniformly mixed with lO.Og of microcrystalline cellulose (Avicel PH102) and 4.0g of ethyl cellulose (EC N50), and further combined with 15.0 g of Surelease comprising 25wt% aqueous ethyl cellulose dispersion.
  • the combination was formulated into granules by use of a hydraulic extrader having a plurality of holes with an inner diameter 2.0 mm, and formulated to long
  • Example 25 20 cylindrical filament, which was then pelletized using a pelletizer. As such, the prepared pellet had a particle size of 1.0-5.0 mm, and a large percentage of the pellet were 1.5-2.5 mm size.
  • Example 25
  • HPC-M hydroxypropyl cellulose
  • Surelease comprising 25wt% aqueous ethyl cellulose dispersion, to which a solution of 0.02g of tamsulosin hydrochloride and 0.15g of poloxamer (Lutrol F 127) in ethanol was added.
  • the mixture was uniformly mixed with 6.0g of corn starch, 6.0g of microcrystalline cellulose, 0.5 g of magnesium stearate, and 1.0 g of talc, and combined with 13.0g of 20wt% Surelease obtained by diluting 25wt% Surelease with water.
  • a molding process of thusly obtained combination to a filament and a pellet was performed in the same manner as in the above examples 1-8.
  • the prepared pellet had a particle size of 1.0-5.0 mm, and a large percentage of the pellet were 1.5-2.5 mm in size.
  • tamsulosin hydrochloride and O.lg of sodium alginate were dissolved in a proper amount of water.
  • the solution was uniformly mixed with lO.Og of microcrystalline cellulose (Avicel PH102), 0.5 g of magnesium stearate, and 1.0 g of talc, and combined with 5.5g of Surelease comprising 25wt% aqueous ethyl cellulose dispersion, and a proper amount of ethanol.
  • a molding process of thusly obtained combination to a filament and a pellet was performed in the same manner as in the above examples 1-8.
  • the prepared pellet had a particle size of 1.0-5.0 mm, and a large percentage of the pellet were 1.5-2.5 mm in size.
  • tamsulosin hydrochloride 0.02g of tamsulosin hydrochloride, 0.05g of poloxamer (Lutrol F 127) and O.lg of sodium alginate (NAPH) were dissolved in water.
  • the solution was uniformly mixed with 5.0g of microcrystalhne cellulose (Avicel PH102), 5.0g of sodium alginate (NSPH), 5.0g of magnesium trisilicate, 0.5g of magnesium stearate and 1.0 g of talc, and combined with 16.6g of Surelease comprising 25wt% aqueous ethyl cellulose dispersion, and a proper amount of ethanol.
  • a molding process of thusly obtained combination to a filament and a pellet was performed in the same manner as in the above examples 1-8.
  • the prepared pellet had a particle size of 1.0-5.0 mm, and a large percentage of the pellet were 1.5-2.5 mm in size.
  • an aqueous, solution of tamsulosin hydrochloride and poloxamer (Lutrol F 127), or a solution of sodium alginate dissolved in the above aqueous solution was uniformly mixed with microcrystalline cellulose (Avicel PHI 02), sodium alginate, alginic acid, and magnesium trisilicate, and further combined with Surelease comprising 25wt% aqueous ethyl cellulose dispersion, or water-diluted Surelease.
  • a molding process of thusly obtained combination to a filament and a pellet was performed in the same manner as in the above examples 1-8.
  • the prepared pellet was dried at 50°C for 6 hours, each of which was coated with Surelease diluted to 15wt% with water using a spray coater.
  • a molding process of thusly obtained combination to a filament and a pellet was performed in the same manner as in the above examples 1-8.
  • the prepared pellets were dried at 50°C for 6 hours, each of which was coated with 30.0g of 25wt% water/ethanol solution of hydroxypropyl methylcellulose (90SH 4,000) using a spray coater.
  • a liquid 1 ml of perchloric acid added to 450 ml of water is controlled by sodium hydroxide to be 2.0 in pH, and then is further added with water to have a total volume of 500 ml.
  • RSD relative standard deviation
  • the formulation prepared by the method of the present invention has similar release properties to the commercially available formulation but 100% release of the inventive formulation can be realized within 24 hours, compared to the commercially available formulation.
  • Examples 35-40 lOg of phenylpropanolamine hydrochloride and 2 g of PNP K-30 were completely dissolved in lOg of ethanol. This solution was mixed with 82g of lactose, 5 g of corn starch and 1 g of magnesium stearate as a lubricant, and combined with an excipient.
  • the combination was extruded by use of a hydraulic extrader to a cylindrical filament, which was then introduced into a pelletizer having two rollers rotating in opposite directions, to prepare a pellet having a diameter of 3 mm. Such pellet was dried at 50°C for 6 hours.
  • pellets of 6-7 mesh were collected and coated with a coating agent having a composition shown in the following Table 7 by use of a spray coater.
  • the combination was introduced into an extruder, and extruded by use of the hydraulic extrader to a cylindrical filament, which was then introduced into a pelletizer having two rollers rotating in opposite directions, to prepare a pellet having a diameter of 3mm. Such pellet was dried at 50°C for 6 hours. Of the prepared pellets, pellets of 6-7 mesh were collected and coated with a coating agent having a composition shown in the following Table 8 by use of a spray coater.
  • the sample obtained from the above example 44 was subjected to dissolution test.
  • the dissolution test was performed at 100 rpm at 37 ⁇ 0.5°C according to the 1 st
  • the present invention provides a method of manufacturing a controlled release formulation using a pelletizer, which is advantageous in terms of remarkably decreased drag loss during a production process of the formulation, and production of the formulation having a uniform amount of a drug.
  • a pellet having various sizes can be molded by adjusting an inner diameter of holes formed in an extruder and of semicircular grooves between neighboring protruded portions formed along each rolling surface of molding rollers provided to the pelletizer. As necessary, a multi-layered pellet can be manufactured, thereby realizing various release controls.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne un procédé qui permet de fabriquer une formulation à libération contrôlée à l'aide d'un pastilleur, selon lequel on extrude une combinaison contenant un médicament en un filament, et on moule le filament en une pastille. On obtient une combinaison possédant une ductilité appropriée en dissolvant dans un solvant au moins un médicament et un polymère hydrophile ou un tensio-actif destiné à faciliter la dissolution du médicament, de façon à obtenir un mélange, et en combinant le mélange avec un diluant inerte et/ou un inhibiteur de dissolution. Le procédé de l'invention offre l'avantage qu'il empêche la perte du médicament au cours de la production de la formulation, et qu'il permet par conséquent de produire une formulation comprenant une quantité uniforme de médicament.
PCT/KR2003/000660 2002-11-29 2003-04-02 Procede permettant de fabriquer une formulation a liberation controlee au moyen d'un pastilleur Ceased WO2004050064A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003219575A AU2003219575A1 (en) 2002-11-29 2003-04-02 Method of manufacturing controlled release formulation using pelletizer

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2002-0075511A KR100510270B1 (ko) 2002-11-29 2002-11-29 펠렛타이저를 이용한 서방성 제제의 제조방법
KR10-2002-0075511 2002-11-29

Publications (1)

Publication Number Publication Date
WO2004050064A1 true WO2004050064A1 (fr) 2004-06-17

Family

ID=32464467

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2003/000660 Ceased WO2004050064A1 (fr) 2002-11-29 2003-04-02 Procede permettant de fabriquer une formulation a liberation controlee au moyen d'un pastilleur

Country Status (3)

Country Link
KR (1) KR100510270B1 (fr)
AU (1) AU2003219575A1 (fr)
WO (1) WO2004050064A1 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006005512A1 (fr) * 2004-07-14 2006-01-19 Siegfried Generics International Ag Granules permettant la liberation controlee de tamsulosine
EP2047847A1 (fr) * 2007-10-12 2009-04-15 KRKA, tovarna zdravil, d.d., Novo mesto Composition pharmaceutique solide comprenant de la tamsulosine
WO2009047312A1 (fr) * 2007-10-12 2009-04-16 Krka, Tovarna Zdravil, D.D., Novo Mesto Composition pharmaceutique solide comprenant de la tamsulosine
CN119405627A (zh) * 2025-01-08 2025-02-11 安若维他药业泰州有限公司 一种基于速溶包衣的坦索罗辛缓释胶囊及其制备方法

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100774774B1 (ko) * 2006-07-20 2007-11-07 일동제약주식회사 메트포르민 서방성 제제 및 그 제조방법

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB747914A (en) * 1953-03-30 1956-04-18 Smith Kline & French Internat Improvements in or relating to pharmaceutical tablet or pellet and method of preparing the same
WO1999006045A1 (fr) * 1997-08-01 1999-02-11 Elan Corporation, Plc Compositions pharmaceutiques a liberation lente, contenant de la tiagabine
WO1999037302A1 (fr) * 1998-01-22 1999-07-29 Abbott Laboratories Formulations de tiagabine a liberation prolongee entrainant moins d'effets secondaires
WO2001008665A1 (fr) * 1999-08-03 2001-02-08 Farmaceutici Formenti S.P.A. Compositions a liberation de paracetamol controlee

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4938968A (en) * 1988-07-26 1990-07-03 Norjec Development Associates, Inc. Controlled release indomethacin
FI101039B (fi) * 1992-10-09 1998-04-15 Eeva Kristoffersson Menetelmä lääkepellettien valmistamiseksi
US5871776A (en) * 1995-01-31 1999-02-16 Mehta; Atul M. Controlled-release nifedipine
JP4020983B2 (ja) * 1995-07-07 2007-12-12 帝國製薬株式会社 持続性製剤およびその製法
DE19901692C2 (de) * 1999-01-18 2002-06-20 Gruenenthal Gmbh Verfahren zur Herstellung von Pellets mit einem Gehalt von bis zu 90 Gew.% eines pharmazeutischen Wirkstoffes

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB747914A (en) * 1953-03-30 1956-04-18 Smith Kline & French Internat Improvements in or relating to pharmaceutical tablet or pellet and method of preparing the same
WO1999006045A1 (fr) * 1997-08-01 1999-02-11 Elan Corporation, Plc Compositions pharmaceutiques a liberation lente, contenant de la tiagabine
WO1999037302A1 (fr) * 1998-01-22 1999-07-29 Abbott Laboratories Formulations de tiagabine a liberation prolongee entrainant moins d'effets secondaires
WO2001008665A1 (fr) * 1999-08-03 2001-02-08 Farmaceutici Formenti S.P.A. Compositions a liberation de paracetamol controlee

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
RUDOLF VOIGT: "Pharmazeutische Technologie fuer Studium und Beruf", 1993, ISBN: 3-86126-013-1 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006005512A1 (fr) * 2004-07-14 2006-01-19 Siegfried Generics International Ag Granules permettant la liberation controlee de tamsulosine
EP1618873A1 (fr) * 2004-07-14 2006-01-25 Siegfried Generics International AG Granule pour la libération contrôlée du tamsulosin, contenant de l'alginate
EP2047847A1 (fr) * 2007-10-12 2009-04-15 KRKA, tovarna zdravil, d.d., Novo mesto Composition pharmaceutique solide comprenant de la tamsulosine
WO2009047312A1 (fr) * 2007-10-12 2009-04-16 Krka, Tovarna Zdravil, D.D., Novo Mesto Composition pharmaceutique solide comprenant de la tamsulosine
CN119405627A (zh) * 2025-01-08 2025-02-11 安若维他药业泰州有限公司 一种基于速溶包衣的坦索罗辛缓释胶囊及其制备方法

Also Published As

Publication number Publication date
KR20040047347A (ko) 2004-06-05
AU2003219575A1 (en) 2004-06-23
KR100510270B1 (ko) 2005-08-26

Similar Documents

Publication Publication Date Title
JP5607670B2 (ja) 時限拍動性薬物送達システム
AU750617B2 (en) Multiple unit controlled food effect-independent release pharmaceutical preparations and method for preparing the same
US6245351B1 (en) Controlled-release composition
KR101157220B1 (ko) 리팍시민을 포함하는 위내성 약학적 제제
JP5642691B2 (ja) ジアセレインを含有する医薬組成物
CN109562072B (zh) 包括含有盐酸坦索罗辛的缓释丸粒的具有受控的溶出度的用于口服给药的药物制剂
JPH0710773B2 (ja) 一定の放出性及び即時放出性を有する薬物粒子
JP3134187B2 (ja) 放出制御組成物
WO2002024174A2 (fr) Composition a liberation prolongee contenant de la clarithromycine
CN1744889A (zh) 坦洛新的控释药物组合物
WO2011037976A2 (fr) Formulations pharmaceutiques de pramipexole
EP1653932A1 (fr) Compositions a liberation modifiee de minocycline
MXPA06008854A (es) Mini tabletas de clorhidrato de venlafaxina de liberacion prolongada recubiertas.
WO2001080824A2 (fr) Formes de dosage a liberation a modifiee a double mecanisme pour medicaments faiblement doses
WO2009101658A1 (fr) Préparation pharmaceutique à libération programmée
JP2009191034A (ja) 時限放出製剤
KR100510270B1 (ko) 펠렛타이저를 이용한 서방성 제제의 제조방법
US20090136550A1 (en) Modified release formulations of diltiazem
KR100774613B1 (ko) 수불용성 고분자로 이루어진 서방형 약물 전달체
WO2025242589A1 (fr) Formes posologiques pharmaceutiques pour thérapie combinée de défériprone et de déférasirox
JP2007515464A (ja) 医薬組成物用ペレットの製造方法
CA3008197A1 (fr) Composition pharmaceutique a liberation pulsatile comprenant de la naftazone ou un de ses sels
MXPA01002821A (en) Multiple unit controlled food effect-independent release pharmaceutical preparations and method for preparing the same

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP